Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC CCs) (U01) | Apply Online

Opportunity Summary:

The National Institutes of Health (NIH) funding opportunity RFA-DK-14-027 supports the creation of a multi-site clinical research consortium focused on chronic pancreatitis (CP), pancreatogenic (type 3c) diabetes (T3cDM), and pancreatic cancer risk, using a U01 cooperative agreement mechanism. The overall aim is to build a coordinated network that can systematically study how chronic pancreatitis develops over time, why some patients progress to major complications like chronic pain and pancreatic insufficiency, how CP relates to T3cDM, and how diabetes and pancreatic cancer are connected, especially in people with newly diagnosed diabetes. The consortium structure is designed to bring together clinical care, epidemiology, and biological sample analysis at a scale that single institutions typically cannot achieve on their own.

This FOA specifically solicits applications for up to nine Clinical Centers (CCs). In parallel, NIH also solicits a separate but linked application for a single Coordination and Data Management Center (CDMC) under a different announcement (RFA-DK-14-028). The expectation is that the CCs will recruit and deeply characterize patients across key groups, including children and adults with chronic pancreatitis and those with acute recurrent pancreatitis (ARP), along with patients who have T3cDM or are newly diagnosed with diabetes. The clinical centers are meant to serve as the patient-facing engines of the consortium, enrolling participants, collecting standardized clinical and epidemiologic data, and contributing biospecimens and follow-up information needed to understand disease progression and cancer risk.

A central scientific emphasis is comprehensive characterization, meaning the consortium is expected to collect harmonized, high-quality information spanning clinical history, imaging and diagnostic findings, risk factors, outcomes, and biological measurements. By combining these data across multiple sites, the consortium can identify patterns and subtypes of disease, explore mechanisms that drive CP and its sequelae, and evaluate factors that may signal elevated risk for pancreatic cancer. In addition to studying CP-related cancer risk, the consortium is also tasked with investigating pancreatic cancer development among people with newly diagnosed diabetes, reflecting growing interest in diabetes as a potential early indicator or risk state for pancreatic cancer in certain patients.

Collaboration is built into the program design rather than treated as optional. Clinical centers are expected to form multidisciplinary teams and to work across the consortium, sharing results and developing trans-consortium projects that leverage the combined expertise, patient populations, and technical capabilities distributed across sites. Because the awards are cooperative agreements (U01), the program is intended to involve substantial NIH scientific and programmatic involvement, with coordinated decision-making and shared infrastructure rather than fully independent, investigator-initiated projects.

A major shared deliverable is the creation of an annotated biospecimen repository to support biomarker discovery and validation. The FOA highlights collection of blood, pancreatic and duodenal juice, stool samples, and, when feasible, pancreatic tissue. The intent is to link these biospecimens to well-annotated clinical data so researchers can identify and validate biomarkers useful for risk stratification and/or early detection, particularly for pancreatic cancer in high-risk settings such as chronic pancreatitis, T3cDM, and new-onset diabetes. This repository approach supports both near-term studies within the consortium and longer-term research value, since carefully collected and curated samples can be used to test emerging hypotheses and technologies over time.

From an administrative standpoint, the opportunity falls under NIH discretionary funding and uses the cooperative agreement funding instrument. The program was posted October 17, 2014, with an original and current closing date of April 2, 2015, and an archive date of May 3, 2015. The estimated total funding amount listed is $6,000,000, and the award ceiling is $270,000 (as provided in the source data). No cost sharing or matching is required.

Eligibility is broad and includes many common NIH applicant types, such as nonprofit organizations (including 501(c)(3) entities), public and private institutions of higher education, small businesses, for-profit organizations other than small businesses, and a range of government entities (state, county, city/township, special district). The announcement also notes eligibility considerations for certain institution types such as HBCUs, Hispanic-serving institutions, tribal colleges and universities, and Alaska Native and Native Hawaiian-serving institutions, among others. Non-U.S. (non-domestic) entities and foreign institutions are not eligible to apply directly, but non-domestic components of U.S. organizations may participate, and foreign components (as defined by NIH policy) are allowable.

In practical terms, an applicant Clinical Center would be proposing to serve as one node in a national network: recruiting and following well-defined patient groups, collecting standardized clinical data and biospecimens, contributing to shared protocols and governance, and participating in cross-site analyses aimed at clarifying disease mechanisms and improving early detection and risk prediction for pancreatic cancer in the settings of chronic pancreatitis and diabetes. The full announcement is linked in the provided record at http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-027.html.

Browse more business programs for Diabetes Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Food and Nutrition Health

Next opportunity: MEPI Local Grants Annual Program Statement

Previous opportunity: FY15 Capital and Debt Service Grant and American Disabilities Act Grant to Amtrak

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 14 027

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 14 027) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 14 027", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.